NCT05065021 is a Phase 2 clinical trial of Niraparib in Ovarian Cancer, sponsored by University Health Network, Toronto.

Who is sponsoring NCT05065021?

NCT05065021 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT05065021?

Interventions in NCT05065021: Niraparib, Dostarlimab, Bevacizumab, Paclitaxel.

What condition does NCT05065021 study?

NCT05065021 studies Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer.

Is NCT05065021 still recruiting?

NCT05065021 is currently status unknown. Last updated 17 January 2024.

Last reviewed 2024-01-17 · How we verify

NCT05065021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Status unknown Phase 2 Last updated 17 January 2024

What this trial tests

Phase 2 trial testing Niraparib in Ovarian Cancer in 40 participants. Status unknown.

Timeline

23 February 2023

Primary endpoint
6 June 2025

6 June 2025

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	23 February 2023
Primary completion	6 June 2025
Estimated completion	6 June 2025
Sites	1 location across Canada

Drugs / interventions tested

Niraparib (niraparib) — full drug profile →
Dostarlimab
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Primary Peritoneal Cancer — all drugs for Primary Peritoneal Cancer →
High Grade Serous Cancer — all drugs for High Grade Serous Cancer →

Sponsor

University Health Network, Toronto

Who can join

18 and older, female only, with Ovarian Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to see how useful it is to look at biomarkers in the blood and tumor tissue of participants with ovarian, fallopian tube or primary peritoneal cancer who have previously received treatment with a drug called a PARP inhibitor, and using the results to determine the best treatment for these participants. Biomarkers are molecules such as genes (molecules that contain instructions for the development and function of cells in the body) and proteins that may be used to see how well a body responds to certain treatments.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K. · · 2022 · cited 56× · PMID 35435784 · DOI 10.1080/13543784.2022.2067527
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, et al · · 2022 · cited 25× · PMID 36533080 · DOI 10.3389/fmolb.2022.1073797
Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes.
Ornella MSC, Badrinath N, Kim KA, Kim JH, et al · · 2023 · cited 24× · PMID 37190310 · DOI 10.3390/cancers15082383
Genome instability and crosstalk with the immune response.
Chabanon RM, Danlos FX, Ouali K, Postel-Vinay S. · · 2025 · cited 4× · PMID 41188872 · DOI 10.1186/s13073-025-01509-6
Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.
Clark CA, Yang ES. · · 2023 · cited 4× · PMID 36751656 · DOI 10.36401/jipo-22-15
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer.
Philips TJ, Erickson BK, Thomas SN. · · 2024 · cited 1× · PMID 39839766 · DOI 10.3389/fonc.2024.1503107

Verify or expand the search:

Other trials of Niraparib

Trials testing the same drug.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06682780 — A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
NCT06887933 — A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ov · Phase 4 · not yet recruiting
NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · Phase 1, PHASE2 · withdrawn

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05065021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 17 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05065021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing